Pfizer Media Center - News Releases
First new prescription treatment approved for smoking cessation in nearly a decade, received priority review designation by FDA
---
Addiction to nicotine is a chronic medical condition that makes quitting smoking difficult; Chantix is a breakthrough treatment specifically developed to block nicotine’s effect in the brain
---
Chantix (1 mg twice daily) nearly doubles the likelihood of quitting versus Zyban® (150 mg twice daily) and nearly quadruples the likelihood over placebo
Wednesday, May 17, 2006
Subscribe to:
Post Comments (Atom)
Posts
No comments:
Post a Comment